カテゴリー： 世界, 医療/バイオ, QYResearch

原発性高シュウ酸尿症治療の世界市場インサイト・予測（～2028年）

【英語タイトル】Global Primary Hyperoxaluria Treatment Market Insights, Forecast to 2028

QYResearchが出版した調査資料（QY22JLX10477）・商品コード：QY22JLX10477
・発行会社（調査会社）：QYResearch
・発行日：2022年7月（※2025年版があります。お問い合わせください。）
・ページ数：90
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD4,900 ⇒換算￥744,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD7,350 ⇒換算￥1,117,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD9,800 ⇒換算￥1,489,600見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

COVID-19のパンデミックにより、原発性高シュウ酸尿症治療のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に原発性高シュウ酸尿症治療の世界市場のxxx％を占める「経口」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「タイプ1」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。
原発性高シュウ酸尿症治療の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパの原発性高シュウ酸尿症治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。

原発性高シュウ酸尿症治療のグローバル主要企業には、Oxthera、Dicerna Pharmaceuticals、Allena Pharmaceuticals、Biocodex、Alnylam Pharmaceuticals、Tecoland Corporation、Zhejiang Tianxin Pharmaceutical、Takeda Pharmaceuticals、Wuxi Further Pharmaceuticalなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。

原発性高シュウ酸尿症治療市場は、種類と用途によって区分されます。世界の原発性高シュウ酸尿症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
経口、静脈内、その他

【用途別セグメント】
タイプ1、タイプ2、タイプ3

【掲載地域】
北米：アメリカ、カナダ
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米：メキシコ、ブラジル、アルゼンチン
中東・アフリカ：トルコ、サウジアラビア、UAE

【目次（一部）】

・調査の範囲
- 原発性高シュウ酸尿症治療製品概要
- 種類別市場（経口、静脈内、その他）
- 用途別市場（タイプ1、タイプ2、タイプ3）
- 調査の目的
・エグゼクティブサマリー
- 世界の原発性高シュウ酸尿症治療販売量予測2017-2028
- 世界の原発性高シュウ酸尿症治療売上予測2017-2028
- 原発性高シュウ酸尿症治療の地域別販売量
- 原発性高シュウ酸尿症治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別原発性高シュウ酸尿症治療販売量
- 主要メーカー別原発性高シュウ酸尿症治療売上
- 主要メーカー別原発性高シュウ酸尿症治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模（経口、静脈内、その他）
- 原発性高シュウ酸尿症治療の種類別販売量
- 原発性高シュウ酸尿症治療の種類別売上
- 原発性高シュウ酸尿症治療の種類別価格
・用途別市場規模（タイプ1、タイプ2、タイプ3）
- 原発性高シュウ酸尿症治療の用途別販売量
- 原発性高シュウ酸尿症治療の用途別売上
- 原発性高シュウ酸尿症治療の用途別価格
・北米市場
- 北米の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（アメリカ、カナダ）
・ヨーロッパ市場
- ヨーロッパの原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア）
・アジア太平洋市場
- アジア太平洋の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア）
・中南米市場
- 中南米の原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（メキシコ、ブラジル、アルゼンチン）
・中東・アフリカ市場
- 中東・アフリカの原発性高シュウ酸尿症治療市場規模（種類別、用途別）
- 主要国別の原発性高シュウ酸尿症治療市場規模（トルコ、サウジアラビア）
・企業情報
Oxthera、Dicerna Pharmaceuticals、Allena Pharmaceuticals、Biocodex、Alnylam Pharmaceuticals、Tecoland Corporation、Zhejiang Tianxin Pharmaceutical、Takeda Pharmaceuticals、Wuxi Further Pharmaceutical
・産業チェーン及び販売チャネル分析
- 原発性高シュウ酸尿症治療の産業チェーン分析
- 原発性高シュウ酸尿症治療の原材料
- 原発性高シュウ酸尿症治療の生産プロセス
- 原発性高シュウ酸尿症治療の販売及びマーケティング
- 原発性高シュウ酸尿症治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 原発性高シュウ酸尿症治療の産業動向
- 原発性高シュウ酸尿症治療のマーケットドライバー
- 原発性高シュウ酸尿症治療の課題
- 原発性高シュウ酸尿症治療の阻害要因
・主な調査結果

Primary Hyperoxaluria (PH) is a rare genetic disorder caused by deficiencies in glyoxylate metabolism leading to oxalate deposition primarily in kidneys causing end-stage renal disease. It is an inherited autosomal recessive disorder and can be of three types based on the different responsible genes: type 1 (AGXT) (PH-I), type 2 (GRHPR) (PH-II), and type 3 (HOGA1) (PH-III). Signs and symptoms may include recurrent kidney stones, hematuria, and urinary tract infections (UTIs).
Market Analysis and Insights: Global Primary Hyperoxaluria Treatment Market
Due to the COVID-19 pandemic, the global Primary Hyperoxaluria Treatment market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Oral accounting for % of the Primary Hyperoxaluria Treatment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Type 1 segment is altered to an % CAGR throughout this forecast period.
China Primary Hyperoxaluria Treatment market size is valued at US$ million in 2021, while the US and Europe Primary Hyperoxaluria Treatment are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Primary Hyperoxaluria Treatment landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Primary Hyperoxaluria Treatment include Oxthera, Dicerna Pharmaceuticals, Allena Pharmaceuticals, Biocodex, Alnylam Pharmaceuticals, Tecoland Corporation, Zhejiang Tianxin Pharmaceutical, Takeda Pharmaceuticals and Wuxi Further Pharmaceutical. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Primary Hyperoxaluria Treatment Scope and Segment
Primary Hyperoxaluria Treatment market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Primary Hyperoxaluria Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Oral
Intravenous
Others
Segment by Application
Type 1
Type 2
Type 3
By Company
Oxthera
Dicerna Pharmaceuticals
Allena Pharmaceuticals
Biocodex
Alnylam Pharmaceuticals
Tecoland Corporation
Zhejiang Tianxin Pharmaceutical
Takeda Pharmaceuticals
Wuxi Further Pharmaceutical
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Primary Hyperoxaluria Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Intravenous
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1
1.3.3 Type 2
1.3.4 Type 3
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Primary Hyperoxaluria Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global Primary Hyperoxaluria Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global Primary Hyperoxaluria Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Primary Hyperoxaluria Treatment Sales by Region
2.4.1 Global Primary Hyperoxaluria Treatment Sales by Region (2017-2022)
2.4.2 Global Sales Primary Hyperoxaluria Treatment by Region (2023-2028)
2.5 Global Primary Hyperoxaluria Treatment Revenue by Region
2.5.1 Global Primary Hyperoxaluria Treatment Revenue by Region (2017-2022)
2.5.2 Global Primary Hyperoxaluria Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Primary Hyperoxaluria Treatment Sales by Manufacturers
3.1.1 Global Top Primary Hyperoxaluria Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global Primary Hyperoxaluria Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Primary Hyperoxaluria Treatment in 2021
3.2 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers
3.2.1 Global Primary Hyperoxaluria Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global Primary Hyperoxaluria Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Primary Hyperoxaluria Treatment Revenue in 2021
3.3 Global Primary Hyperoxaluria Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Primary Hyperoxaluria Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Primary Hyperoxaluria Treatment Sales by Type
4.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Type (2017-2022)
4.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
4.2 Global Primary Hyperoxaluria Treatment Revenue by Type
4.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
4.3 Global Primary Hyperoxaluria Treatment Price by Type
4.3.1 Global Primary Hyperoxaluria Treatment Price by Type (2017-2022)
4.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Primary Hyperoxaluria Treatment Sales by Application
5.1.1 Global Primary Hyperoxaluria Treatment Historical Sales by Application (2017-2022)
5.1.2 Global Primary Hyperoxaluria Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
5.2 Global Primary Hyperoxaluria Treatment Revenue by Application
5.2.1 Global Primary Hyperoxaluria Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global Primary Hyperoxaluria Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
5.3 Global Primary Hyperoxaluria Treatment Price by Application
5.3.1 Global Primary Hyperoxaluria Treatment Price by Application (2017-2022)
5.3.2 Global Primary Hyperoxaluria Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America Primary Hyperoxaluria Treatment Market Size by Type
6.1.1 North America Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
6.1.2 North America Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
6.2 North America Primary Hyperoxaluria Treatment Market Size by Application
6.2.1 North America Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
6.2.2 North America Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
6.3 North America Primary Hyperoxaluria Treatment Market Size by Country
6.3.1 North America Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
6.3.2 North America Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Primary Hyperoxaluria Treatment Market Size by Type
7.1.1 Europe Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
7.1.2 Europe Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
7.2 Europe Primary Hyperoxaluria Treatment Market Size by Application
7.2.1 Europe Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
7.2.2 Europe Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
7.3 Europe Primary Hyperoxaluria Treatment Market Size by Country
7.3.1 Europe Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
7.3.2 Europe Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Type
8.1.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Application
8.2.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific Primary Hyperoxaluria Treatment Market Size by Region
8.3.1 Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Primary Hyperoxaluria Treatment Market Size by Type
9.1.1 Latin America Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
9.1.2 Latin America Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
9.2 Latin America Primary Hyperoxaluria Treatment Market Size by Application
9.2.1 Latin America Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
9.2.2 Latin America Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
9.3 Latin America Primary Hyperoxaluria Treatment Market Size by Country
9.3.1 Latin America Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
9.3.2 Latin America Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Type
10.1.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Application
10.2.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa Primary Hyperoxaluria Treatment Market Size by Country
10.3.1 Middle East and Africa Primary Hyperoxaluria Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Oxthera
11.1.1 Oxthera Corporation Information
11.1.2 Oxthera Overview
11.1.3 Oxthera Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Oxthera Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Oxthera Recent Developments
11.2 Dicerna Pharmaceuticals
11.2.1 Dicerna Pharmaceuticals Corporation Information
11.2.2 Dicerna Pharmaceuticals Overview
11.2.3 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Dicerna Pharmaceuticals Recent Developments
11.3 Allena Pharmaceuticals
11.3.1 Allena Pharmaceuticals Corporation Information
11.3.2 Allena Pharmaceuticals Overview
11.3.3 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Allena Pharmaceuticals Recent Developments
11.4 Biocodex
11.4.1 Biocodex Corporation Information
11.4.2 Biocodex Overview
11.4.3 Biocodex Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Biocodex Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Biocodex Recent Developments
11.5 Alnylam Pharmaceuticals
11.5.1 Alnylam Pharmaceuticals Corporation Information
11.5.2 Alnylam Pharmaceuticals Overview
11.5.3 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Alnylam Pharmaceuticals Recent Developments
11.6 Tecoland Corporation
11.6.1 Tecoland Corporation Corporation Information
11.6.2 Tecoland Corporation Overview
11.6.3 Tecoland Corporation Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Tecoland Corporation Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tecoland Corporation Recent Developments
11.7 Zhejiang Tianxin Pharmaceutical
11.7.1 Zhejiang Tianxin Pharmaceutical Corporation Information
11.7.2 Zhejiang Tianxin Pharmaceutical Overview
11.7.3 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Zhejiang Tianxin Pharmaceutical Recent Developments
11.8 Takeda Pharmaceuticals
11.8.1 Takeda Pharmaceuticals Corporation Information
11.8.2 Takeda Pharmaceuticals Overview
11.8.3 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Takeda Pharmaceuticals Recent Developments
11.9 Wuxi Further Pharmaceutical
11.9.1 Wuxi Further Pharmaceutical Corporation Information
11.9.2 Wuxi Further Pharmaceutical Overview
11.9.3 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Wuxi Further Pharmaceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Primary Hyperoxaluria Treatment Industry Chain Analysis
12.2 Primary Hyperoxaluria Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Primary Hyperoxaluria Treatment Production Mode & Process
12.4 Primary Hyperoxaluria Treatment Sales and Marketing
12.4.1 Primary Hyperoxaluria Treatment Sales Channels
12.4.2 Primary Hyperoxaluria Treatment Distributors
12.5 Primary Hyperoxaluria Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Primary Hyperoxaluria Treatment Industry Trends
13.2 Primary Hyperoxaluria Treatment Market Drivers
13.3 Primary Hyperoxaluria Treatment Market Challenges
13.4 Primary Hyperoxaluria Treatment Market Restraints
14 Key Findings in The Global Primary Hyperoxaluria Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Intravenous
Table 4. Major Manufacturers of Others
Table 5. Global Primary Hyperoxaluria Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global Primary Hyperoxaluria Treatment Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global Primary Hyperoxaluria Treatment Sales by Region (2017-2022) & (K Units)
Table 8. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2017-2022)
Table 9. Global Primary Hyperoxaluria Treatment Sales by Region (2023-2028) & (K Units)
Table 10. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2023-2028)
Table 11. Global Primary Hyperoxaluria Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2017-2022)
Table 13. Global Primary Hyperoxaluria Treatment Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region (2023-2028)
Table 15. Global Primary Hyperoxaluria Treatment Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global Primary Hyperoxaluria Treatment Sales Share by Manufacturers (2017-2022)
Table 17. Global Primary Hyperoxaluria Treatment Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global Primary Hyperoxaluria Treatment Revenue Share by Manufacturers (2017-2022)
Table 19. Primary Hyperoxaluria Treatment Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global Primary Hyperoxaluria Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global Primary Hyperoxaluria Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Hyperoxaluria Treatment as of 2021)
Table 22. Primary Hyperoxaluria Treatment Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Primary Hyperoxaluria Treatment Product Offered
Table 24. Date of Manufacturers Enter into Primary Hyperoxaluria Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 27. Global Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 28. Global Primary Hyperoxaluria Treatment Sales Share by Type (2017-2022)
Table 29. Global Primary Hyperoxaluria Treatment Sales Share by Type (2023-2028)
Table 30. Global Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global Primary Hyperoxaluria Treatment Revenue Share by Type (2017-2022)
Table 33. Global Primary Hyperoxaluria Treatment Revenue Share by Type (2023-2028)
Table 34. Primary Hyperoxaluria Treatment Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Primary Hyperoxaluria Treatment Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 37. Global Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 38. Global Primary Hyperoxaluria Treatment Sales Share by Application (2017-2022)
Table 39. Global Primary Hyperoxaluria Treatment Sales Share by Application (2023-2028)
Table 40. Global Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global Primary Hyperoxaluria Treatment Revenue Share by Application (2017-2022)
Table 43. Global Primary Hyperoxaluria Treatment Revenue Share by Application (2023-2028)
Table 44. Primary Hyperoxaluria Treatment Price by Application (2017-2022) & (US$/Unit)
Table 45. Global Primary Hyperoxaluria Treatment Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 47. North America Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 48. North America Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 51. North America Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 52. North America Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America Primary Hyperoxaluria Treatment Sales by Country (2017-2022) & (K Units)
Table 55. North America Primary Hyperoxaluria Treatment Sales by Country (2023-2028) & (K Units)
Table 56. North America Primary Hyperoxaluria Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America Primary Hyperoxaluria Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 59. Europe Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 60. Europe Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 63. Europe Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 64. Europe Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe Primary Hyperoxaluria Treatment Sales by Country (2017-2022) & (K Units)
Table 67. Europe Primary Hyperoxaluria Treatment Sales by Country (2023-2028) & (K Units)
Table 68. Europe Primary Hyperoxaluria Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe Primary Hyperoxaluria Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific Primary Hyperoxaluria Treatment Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific Primary Hyperoxaluria Treatment Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 83. Latin America Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 84. Latin America Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 87. Latin America Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 88. Latin America Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America Primary Hyperoxaluria Treatment Sales by Country (2017-2022) & (K Units)
Table 91. Latin America Primary Hyperoxaluria Treatment Sales by Country (2023-2028) & (K Units)
Table 92. Latin America Primary Hyperoxaluria Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America Primary Hyperoxaluria Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa Primary Hyperoxaluria Treatment Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa Primary Hyperoxaluria Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 106. Oxthera Corporation Information
Table 107. Oxthera Description and Major Businesses
Table 108. Oxthera Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. Oxthera Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. Oxthera Recent Developments
Table 111. Dicerna Pharmaceuticals Corporation Information
Table 112. Dicerna Pharmaceuticals Description and Major Businesses
Table 113. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Dicerna Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Dicerna Pharmaceuticals Recent Developments
Table 116. Allena Pharmaceuticals Corporation Information
Table 117. Allena Pharmaceuticals Description and Major Businesses
Table 118. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Allena Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Allena Pharmaceuticals Recent Developments
Table 121. Biocodex Corporation Information
Table 122. Biocodex Description and Major Businesses
Table 123. Biocodex Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Biocodex Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Biocodex Recent Developments
Table 126. Alnylam Pharmaceuticals Corporation Information
Table 127. Alnylam Pharmaceuticals Description and Major Businesses
Table 128. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Alnylam Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Alnylam Pharmaceuticals Recent Developments
Table 131. Tecoland Corporation Corporation Information
Table 132. Tecoland Corporation Description and Major Businesses
Table 133. Tecoland Corporation Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. Tecoland Corporation Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. Tecoland Corporation Recent Developments
Table 136. Zhejiang Tianxin Pharmaceutical Corporation Information
Table 137. Zhejiang Tianxin Pharmaceutical Description and Major Businesses
Table 138. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Zhejiang Tianxin Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Zhejiang Tianxin Pharmaceutical Recent Developments
Table 141. Takeda Pharmaceuticals Corporation Information
Table 142. Takeda Pharmaceuticals Description and Major Businesses
Table 143. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. Takeda Pharmaceuticals Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Takeda Pharmaceuticals Recent Developments
Table 146. Wuxi Further Pharmaceutical Corporation Information
Table 147. Wuxi Further Pharmaceutical Description and Major Businesses
Table 148. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Wuxi Further Pharmaceutical Primary Hyperoxaluria Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Wuxi Further Pharmaceutical Recent Developments
Table 151. Key Raw Materials Lists
Table 152. Raw Materials Key Suppliers Lists
Table 153. Primary Hyperoxaluria Treatment Distributors List
Table 154. Primary Hyperoxaluria Treatment Customers List
Table 155. Primary Hyperoxaluria Treatment Market Trends
Table 156. Primary Hyperoxaluria Treatment Market Drivers
Table 157. Primary Hyperoxaluria Treatment Market Challenges
Table 158. Primary Hyperoxaluria Treatment Market Restraints
Table 159. Research Programs/Design for This Report
Table 160. Key Data Information from Secondary Sources
Table 161. Key Data Information from Primary Sources
List of Figures
Figure 1. Primary Hyperoxaluria Treatment Product Picture
Figure 3. Global Primary Hyperoxaluria Treatment Market Share by Type in 2021 & 2028
Figure 3. Oral Product Picture
Figure 4. Intravenous Product Picture
Figure 5. Others Product Picture
Figure 6. Global Primary Hyperoxaluria Treatment Market Share by Application in 2021 & 2028
Figure 7. Type 1
Figure 8. Type 2
Figure 9. Type 3
Figure 10. Primary Hyperoxaluria Treatment Report Years Considered
Figure 11. Global Primary Hyperoxaluria Treatment Sales 2017-2028 (K Units)
Figure 12. Global Primary Hyperoxaluria Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global Primary Hyperoxaluria Treatment Revenue 2017-2028 (US$ Million)
Figure 14. Global Primary Hyperoxaluria Treatment Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2017-2022)
Figure 16. Global Primary Hyperoxaluria Treatment Sales Market Share by Region (2023-2028)
Figure 17. North America Primary Hyperoxaluria Treatment Sales YoY (2017-2028) & (K Units)
Figure 18. North America Primary Hyperoxaluria Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe Primary Hyperoxaluria Treatment Sales YoY (2017-2028) & (K Units)
Figure 20. Europe Primary Hyperoxaluria Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific Primary Hyperoxaluria Treatment Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific Primary Hyperoxaluria Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America Primary Hyperoxaluria Treatment Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America Primary Hyperoxaluria Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa Primary Hyperoxaluria Treatment Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa Primary Hyperoxaluria Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The Primary Hyperoxaluria Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of Primary Hyperoxaluria Treatment in the World: Market Share by Primary Hyperoxaluria Treatment Revenue in 2021
Figure 29. Global Primary Hyperoxaluria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 31. Global Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 32. Global Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 33. Global Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 34. North America Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 35. North America Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 36. North America Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 37. North America Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 38. North America Primary Hyperoxaluria Treatment Sales Share by Country (2017-2028)
Figure 39. North America Primary Hyperoxaluria Treatment Revenue Share by Country (2017-2028)
Figure 40. United States Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 41. Canada Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 42. Europe Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 43. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 44. Europe Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 45. Europe Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 46. Europe Primary Hyperoxaluria Treatment Sales Share by Country (2017-2028)
Figure 47. Europe Primary Hyperoxaluria Treatment Revenue Share by Country (2017-2028)
Figure 48. Germany Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 49. France Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 51. Italy Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 52. Russia Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific Primary Hyperoxaluria Treatment Sales Share by Region (2017-2028)
Figure 58. Asia Pacific Primary Hyperoxaluria Treatment Revenue Share by Region (2017-2028)
Figure 59. China Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 60. Japan Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 62. India Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 63. Australia Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 69. Latin America Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 70. Latin America Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 71. Latin America Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 72. Latin America Primary Hyperoxaluria Treatment Sales Share by Country (2017-2028)
Figure 73. Latin America Primary Hyperoxaluria Treatment Revenue Share by Country (2017-2028)
Figure 74. Mexico Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 77. Middle East and Africa Primary Hyperoxaluria Treatment Sales Market Share by Type (2017-2028)
Figure 78. Middle East and Africa Primary Hyperoxaluria Treatment Revenue Market Share by Type (2017-2028)
Figure 79. Middle East and Africa Primary Hyperoxaluria Treatment Sales Market Share by Application (2017-2028)
Figure 80. Middle East and Africa Primary Hyperoxaluria Treatment Revenue Market Share by Application (2017-2028)
Figure 81. Middle East and Africa Primary Hyperoxaluria Treatment Sales Share by Country (2017-2028)
Figure 82. Middle East and Africa Primary Hyperoxaluria Treatment Revenue Share by Country (2017-2028)
Figure 83. Turkey Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 84. Saudi Arabia Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 85. UAE Primary Hyperoxaluria Treatment Revenue (2017-2028) & (US$ Million)
Figure 86. Primary Hyperoxaluria Treatment Value Chain
Figure 87. Primary Hyperoxaluria Treatment Production Process
Figure 88. Channels of Distribution
Figure 89. Distributors Profiles
Figure 90. Bottom-up and Top-down Approaches for This Report
Figure 91. Data Triangulation
Figure 92. Key Executives Interviewed


★調査レポート[原発性高シュウ酸尿症治療の世界市場インサイト・予測（～2028年）] (コード：QY22JLX10477)販売に関する免責事項を必ずご確認ください。
★調査レポート[原発性高シュウ酸尿症治療の世界市場インサイト・予測（～2028年）]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 二次高シュウ酸尿症薬の世界市場インサイト・予測（～2028年）
  • 非感染性ブドウ膜炎治療の世界市場インサイト・予測（～2028年）
  • ホルモン不妊治療の世界市場インサイト・予測（～2028年）
  • ナルコレプシー治療薬の世界市場インサイト・予測（～2028年）
  • 単純疱疹治療の世界市場インサイト・予測（～2028年）

    • ◆H&Iグローバルリサーチのお客様（例）◆